stops the expansion and the work of T cells that attack kill tumor cells
Yervoy and Keytruda, checkpoint inhibitors, increase T cell response, but Gal 3 inhibits it
If you use combo of GRMD2 and Keytruda marked effect on size of tumor, in other cancers and sarcomas...
33 year followup
1) Stage 1 and 2 NASH no increase in mortality
3) Stage 3 , 4 NASH marked increase in mortality
Firat time proved prospectively..Late stage disease is key- 6 million with late disease, 1 million with cirrhosis
ready for P2.
Two designs with fast track via FDA
June 2015 NASH with cirhosis
July 2nd trial